ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,860.73
-0.33%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Corvus Pharmaceuticals Inc (CRVS)

  7. Corvus Pharmaceuticals Inc (CRVS) Noticias

CRVS

Corvus Pharmaceuticals (CRVS)

Corvus Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CRVS
FechaHoraFuenteTítuloSímboloCompañía
07/05/202416:19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CRVSCorvus Pharmaceuticals Inc
07/05/202416:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRVSCorvus Pharmaceuticals Inc
07/05/202416:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/05/202415:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/05/202415:01GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
02/05/202415:02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024NASDAQ:CRVSCorvus Pharmaceuticals Inc
02/05/202407:30GlobeNewswire Inc.Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct OfferingNASDAQ:CRVSCorvus Pharmaceuticals Inc
09/04/202415:01GlobeNewswire Inc.Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisNASDAQ:CRVSCorvus Pharmaceuticals Inc
19/03/202415:02GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
19/03/202406:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:CRVSCorvus Pharmaceuticals Inc
13/03/202415:02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024NASDAQ:CRVSCorvus Pharmaceuticals Inc
12/02/202407:30GlobeNewswire Inc.Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory DiseasesNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/02/202415:27Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CRVSCorvus Pharmaceuticals Inc
08/02/202415:05GlobeNewswire Inc.Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaNASDAQ:CRVSCorvus Pharmaceuticals Inc
06/02/202415:05GlobeNewswire Inc.Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business OfficerNASDAQ:CRVSCorvus Pharmaceuticals Inc
23/01/202416:00GlobeNewswire Inc.Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. MitchellNASDAQ:CRVSCorvus Pharmaceuticals Inc
09/12/202311:00GlobeNewswire Inc.Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma TrialNASDAQ:CRVSCorvus Pharmaceuticals Inc
07/11/202315:01GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
02/11/202308:15GlobeNewswire Inc.Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & ExpositionNASDAQ:CRVSCorvus Pharmaceuticals Inc
01/11/202318:31GlobeNewswire Inc.Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune DiseasesNASDAQ:CRVSCorvus Pharmaceuticals Inc
31/10/202315:02GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023NASDAQ:CRVSCorvus Pharmaceuticals Inc
06/09/202315:05GlobeNewswire Inc.Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDANASDAQ:CRVSCorvus Pharmaceuticals Inc
08/08/202315:01GlobeNewswire Inc.Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:CRVSCorvus Pharmaceuticals Inc
01/08/202307:30GlobeNewswire Inc.Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023NASDAQ:CRVSCorvus Pharmaceuticals Inc
06/07/202311:59GlobeNewswire Inc.Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)NASDAQ:CRVSCorvus Pharmaceuticals Inc
29/06/202306:00GlobeNewswire Inc.Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International ConferenceNASDAQ:CRVSCorvus Pharmaceuticals Inc
21/06/202305:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CRVSCorvus Pharmaceuticals Inc
20/06/202316:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CRVSCorvus Pharmaceuticals Inc
15/06/202306:00GlobeNewswire Inc.Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant LymphomaNASDAQ:CRVSCorvus Pharmaceuticals Inc
31/05/202307:30GlobeNewswire Inc.Corvus Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:CRVSCorvus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CRVS

Su Consulta Reciente

AMEX
SCHJ
Schwab 1 to 5 Year Corpo...
BTRX
MFABTC
BIT
C00180
Commerzbank
USOTC
REPYF
Repsol YPF (QX)
LSE
NARS
Nationwide Accident Repair Svc
LSE
0T9J
Orex Minerals
NYSE
YETI
YETI
USOTC
MAEOY
Manila Electric (PK)
NASDAQ
AACG
ATA Creativity Global
NASDAQ
NWBI
Northwest Bancshares
BOV
PETRT340
PETRT340 Ex:31,12
LSE
IVZ
LSE
0V5H
Manulife Financial
GEMN
MATICUSD
Polygon
USOTC
RAIFF
Raiffeisen Bank (PK)
FX
UZSEUR
UZS vs Euro
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados